Alpha 2.0
Login Register
» Authors » Corinne Courbon

Corinne Courbon

Explore the profile of Corinne Courbon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 12
Followers 0
Related Specialty
Oncology
Top 10 Co-Authors
Ibrahim Yakoub-Agha
Franciane Paul
Celine Vicente
Anne-Sophie Moreau
Jean-Jacques Tudesq
Arthur Sterin
Cecile Pochon
Jacques-Olivier Bay
Muriel Picard
Mathilde Yakoub-Agha
Published In
Bull Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]
Picard M, Sterin A, Bay J, Courbon C, Moreau A, Paul F, et al.
Bull Cancer . 2022 Jan; 110(2S):S123-S131. PMID: 35094839
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is...
2.
[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]
Tudesq J, Yakoub-Agha M, Bay J, Courbon C, Paul F, Picard M, et al.
Bull Cancer . 2021 Dec; 110(2S):S116-S122. PMID: 34895696
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such...
3.
[Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Paul F, Vicente C, Courbon C, Moreau A, Picard M, Pochon C, et al.
Bull Cancer . 2021 Dec; 108(12S):S90-S97. PMID: 34876272
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms...
4.
[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]
Pochon C, Courbon C, Bay J, Moreau A, Paul F, Picard M, et al.
Bull Cancer . 2021 Nov; 108(12S):S98-S103. PMID: 34802718
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell...
5.
[The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Beauvais D, Andrianne C, Aubrun C, Berquier M, Bole S, Caulier A, et al.
Bull Cancer . 2020 Sep; 107(12S):S170-S177. PMID: 32891406
In Europe, two CAR T-cell products, tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), were approved in 2018. While these treatments are available for use, allogeneic hematopoietic stem cell transplantation centers still...
6.
[National care logbook for patients undergoing autologous hematopoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Porcheron S, Balcaen S, Cardinael N, Courbon C, Dendoncker C, Faivre-Lescat H, et al.
Bull Cancer . 2017 Nov; 104(12S):S142-S144. PMID: 29128082
In an attempt to harmonize clinical practices among French hematopoietic stem cell transplantation centers, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held its seventh annual workshop...